Stemtech Revenue Plunges 43% to $2.88M in FY25 Amid Supply Issues
STEK has more than doubled off its 52-week low of $0 on light trading volume (0.1× avg).
Summary
Stemtech Corp reported a significant 43.1% revenue decline to $2.876 million for fiscal year 2025, with net losses widening to $4.047 million. The company attributed the revenue drop primarily to product stock-outs and supply disruptions. While diluted EPS improved slightly to $(0.02), the overall financial performance indicates severe operational challenges for this micro-cap company. Management has secured $2.5 million in April 2026 financing to produce inventory and address supply constraints, which is a critical step towards recovery.
At the time of this announcement, STEK was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $46.4K. The 52-week trading range was $0.00 to $0.04. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.